Articles from Orum Therapeutics

Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Dorin Toader, Ph.D., as Head of Platform Technology. Dr. Toader brings more than 27 years of experience in drug discovery, including over 15 years in antibody-drug conjugates (ADCs). He will be responsible for defining and executing Orum’s technology vision, leading efforts across chemistry and antibody engineering, and guiding innovation in payload design, conjugation technologies, linker–payload strategies, structural biology, and computational modeling to advance Orum’s Dual-Precision Targeted Protein Degradation (TPD²) approach and expand its therapeutic applications.

Orum Therapeutics (“Orum” or the “Company”), a biopharmaceutical company pioneering the field of degrader-antibody conjugates (DACs) based on its Dual-Precision Targeted Protein Degradation, TPD2®, approach, today announced that it has filed a registration statement with the Financial Supervisory Service to list on the KOSDAQ market and will begin the initial public offering process. DACs are considered as a next-generation therapeutic modality that can selectively deliver targeted protein degradation (TPD) agents to target cells via antibodies and degrade proteins of interest within the cell to treat disease.

Orum Therapeutics (“Orum” or the “Company”), a clinical-stage private biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals (“Vertex”) (Nasdaq: VRTX) rights to conduct research using Orum’s Dual-Precision Targeted Protein Degradation (TPD²®) technology for the discovery of novel targeted conditioning agents for use with gene editing.

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation of positive preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia (AML), at the 64th American Society of Hematology (ASH 2022) Annual Meeting & Exposition taking place December 10-13 in New Orleans and virtually. ORM-6151 is the second drug candidate from Orum’s Dual-Precision Targeted Protein Degradation (TPD2 TM) approach, which combines the catalytic mechanism of TPDs with the precision of tumor-targeting therapeutic antibodies.

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation of preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia (AML). The data will be presented at the 64th American Society of Hematology (ASH 2022) Annual Meeting & Exposition taking place December 10-13, in New Orleans.

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the first patient has been dosed with ORM-5029 in a Phase 1 clinical trial for patients with HER2-expressing advanced solid tumors. ORM-5029 is one of two lead programs from the company’s GSPT1 platform leveraging the Dual-Precision Targeted Protein Degradation (TPD²) approach, which is designed to leverage antibody drug conjugates (ADCs) to precisely deliver and target intracellular proteins for degradation leading to cancer cell death.

Orum Therapeutics, a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the Company’s leadership will participate in the following investor conferences:

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today presented preclinical data for ORM-5029, a potential first-in-class TPD therapy for HER2-positive cancers, at the American Association for Cancer Research (“AACR”) Annual Meeting 2022. ORM-5029 is one of two lead programs from the company’s Antibody neoDegrader Conjugate (AnDC™) platform based on its Dual-Precision Targeted Protein Degradation (TPD²) approach.

Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders to treat cancer, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the Orum Therapeutics team on the development of Orum’s novel targeted protein degraders (TPD) that use Orum’s TPD²™ approach, which combines the power of protein degradation with the precise tumor cell delivery mechanism of an antibody.

Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders to treat cancer, today announced the appointment of David Main to the Company’s Board of Directors. Mr. Main is a highly experienced biopharmaceutical executive who has more than 30 years of industry leadership experience with a strong track record of value creation and company growth.

Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, today announced that the Company’s leadership will participate in the following virtual conferences:

Orum Therapeutics, a preclinical biotech pioneering the development of tumor-directed targeted protein degraders to improve cancer treatment, today announced the appointment of Olaf Christensen, M.D., as Chief Medical Officer. He will lead the clinical development of Orum’s first-in-class targeted protein degraders from the company’s Antibody neoDegrader Conjugate (AnDC) platform.

Orum Therapeutics, a biotech company pioneering the development of targeted protein degraders to treat cancer, today announced the close of a $84 million Series B financing. This includes a previously announced $30 million financing and $54 million in new funds led by IMM Investment and joined by new investors (KDB Investment and Atinum, among others) and existing investors (Intervest and KB Investment, among others). Orum plans to use the proceeds to advance the Company’s lead therapeutic candidates into clinical trials, explore additional payload chemistries to develop additional payloads that modulate the ubiquitin pathway, and other general corporate purposes.

Orum Therapeutics, a global biotech company pioneering the development technologies for precision delivery of targeted protein degraders to treat cancer, today announced the appointment of Jae Won Kim as Chief Financial Officer.